Vincerx Pharma, INC 10-Q quarterly reports
Quarterly reports, with unaudited financial statements and management’s discussion of the quarter just ended.
OTC.Pink
Vincerx Pharma's board of directors has approved a plan to dissolve, liquidate, and wind-up the company due to limited cash resources and the inability to raise capital.
OTC.Pink
Vincerx Pharma's Q3 2024 report details ongoing clinical trials, financial results, and a focus on advancing their oncology pipeline despite continued operating losses.
OTC.Pink
Vincerx Pharma's Q2 2024 report details a net loss of $1.8 million, alongside updates on clinical programs and financial activities.
OTC.Pink
Vincerx Pharma reports a net loss of $12.4 million for the first quarter of 2024, alongside a recent capital raise of $17.8 million.